Ceronie, Bryan
Jacobs, Benjamin M.
Baker, David http://orcid.org/0000-0002-8872-8711
Dubuisson, Nicolas
Mao, Zhifeng
Ammoscato, Francesca
Lock, Helen
Longhurst, Hilary J.
Giovannoni, Gavin
Schmierer, Klaus
Funding for this research was provided by:
Multiple Sclerosis Society
Article History
Received: 7 February 2018
Revised: 5 March 2018
Accepted: 8 March 2018
First Online: 17 March 2018
Compliance with ethical standards
:
: GG has received fees for participation in advisory board and speaker fees for Merck. KS has received honoraria and meeting support from Merck. However, Merck was not involved in this study design or its implementation. Other disclosures are considered not relevant but: BC has nothing to declare, BMJ has nothing to declare; DB is a shareholder and consultant to Canbex therapeutics and has received research support from Sanofi-Genzyme; ND has nothing to declare; ZM has nothing to declare; GG has received fees for participation in advisory board from AbbVie Biotherapeutics, Biogen, Canbex, Ironwood, Novartis, Merck, Roche, Sanofi-Genzyme, Synthon, Teva and Vertex; speaker fees from AbbVie, Biogen, Bayer HealthCare, Genzyme, Sanofi-Aventis and Teva. Research support from Biogen, Genzyme, Ironwood, Merck, Merck Serono, Novartis and Takeda. KS has been a PI of trials sponsored by Novartis, Roche and Teva and involved in trials sponsored by Biogen, Sanofi-Genzyme, BIAL, Cytokinetics, and Canbex and has received honoraria and meeting support from Biogen, Novartis, and Teva.
: The study was approved by the Health and Social Care Research Ethics Committee B and the Health Research Authority, UK. People were recruited following informed consent. Purchased blood samples were collected with informed consent and did not require additional ethical review.